Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.

@article{Hauber2000SavingsIT,
  title={Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.},
  author={A. Brett Hauber and Ari Gnanasakthy and Josephine A. Mauskopf},
  journal={Clinical therapeutics},
  year={2000},
  volume={22 4},
  pages={439-51}
}
OBJECTIVE To estimate per-patient potential cost savings using rivastigmine in the treatment of Alzheimer's disease (AD) in Canada. BACKGROUND In recent years, new members of a class of pharmaceuticals known as cholinesterase inhibitors have been introduced for the treatment of patients with AD. Two recent studies conducted in the United Kingdom and the United States estimated potential cost savings from the new cholinesterase inhibitor rivastigmine. The present study combined the disease… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Rivastigmine for Alzheimer's disease.

The Cochrane database of systematic reviews • 2015

Systematic review of economic evaluations of Alzheimer's disease medications.

Expert review of pharmacoeconomics & outcomes research • 2008

Similar Papers

Loading similar papers…